0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响

目的:评价0.1%他扎罗汀乳膏短时接触隔日维持治疗对寻常痤疮复发的影响及其安全性.方法:采用多中心、随机、双盲、安慰剂对照方法,对纳入观察的126例经治疗后症状缓解达到Pillsbury分级法属I级以下的寻常痤疮患者.采用0.1%他扎罗汀乳膏(或安慰剂)短时接触隔日维持治疗,按Doshi的痤疮综合分级系统(the global ache grading system,GAGS)计分评价,观察维持疗程第4、8、12周症状变化情况,评估其对症状复发的影响.结果:0.1%他扎罗汀乳膏维持治疗组较安慰剂组的复发率明显降低,在随访的第8和12周复发率差异有统计学意义(χ~2=5.255和8.147,P<0.05);两组无论是轻、中、重度,还是局部不良反应发生率均相近,发生率极低.总的局部不良反应发生率(3.33%/1.69%)比较差异无统计学意义(χ~2=0.325、P>0.05).结论:0.1%他扎罗汀乳膏短时接触隔日维持治疗能减少寻常痤疮复发,且局部不良反应少,具有一定的临床应用价值.

A clinical study of tazarotene cream of short-term maintaining therapy every other day on the relapse of acne vulgaris

Objective: To investigate the effect of 0.1% tazarotene cream in short-contact maintaining therapy on the relapseof acne vulgaris. Methods: A multicenter, randomized, double-blind, placebo-controlled method was served in the study. Onehundred and twenty-six patients of acne vulgaris whose conditions had reached grade I after treatment according to Pillsbury's classification standard were enrolled and divided into group A (tazarotene group) and group B (placebo). All patients wereevaluated by Doshi's global acne grading system (GAGS). Then maintaining treatment was lasted for 12 weeks, and the condition of relapse was evaluated at 4, 8 and 12 weeks. Results: In group A which received tazarotene treatment the relapserate was markedly lower than in control group (group B), the corresponding follow-up at 4,8 weeks after treatment revealedlower relapse rate than in control (group B)(χ~2 = 5.255 and 8.147,P< 0.05). There was no significant difference in regionalside-effect in group A and group B no matter of mild, moderate or sever conditions. Conclusions: Short-contact maintainingtherapy of 0.1% tazarotene cream could reduce the relapse rate of acne vulgaris patients, regional side-effect was acceptablewhich suggested an applying value of the treatment in clinics.